1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24355
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSaridaki, Z.en
dc.contributor.authorPappas, P.en
dc.contributor.authorSouglakos, J.en
dc.contributor.authorNikolaidou, M.en
dc.contributor.authorVardakis, N.en
dc.contributor.authorKotsakis, A.en
dc.contributor.authorMarselos, M.en
dc.contributor.authorGeorgoulias, V.en
dc.contributor.authorMavroudis, D.en
dc.date.accessioned2015-11-24T19:40:27Z-
dc.date.available2015-11-24T19:40:27Z-
dc.identifier.issn1432-0843-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24355-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverseen
dc.subjecteffects/pharmacokineticsen
dc.subjectDeoxycytidine/administration & dosage/analogs & derivativesen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Interactionsen
dc.subjectFemaleen
dc.subjectFever/chemically induceden
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMaximum Tolerated Doseen
dc.subjectMiddle Ageden
dc.subjectNeoplasms/*drug therapyen
dc.subjectNeutropenia/*chemically induceden
dc.subjectOrganoplatinum Compounds/administration & dosageen
dc.subjectPaclitaxel/administration & dosageen
dc.titleA dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumorsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s00280-009-1013-x-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/19415279-
heal.identifier.secondaryhttp://www.springerlink.com/content/e906t7010254p3u7/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2009-
heal.abstractPURPOSE: To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTDs) of the paclitaxel, gemcitabine, oxaliplatin combination administered biweekly in patients with advanced solid tumors. PATIENTS AND METHODS: Patients received escalated doses of paclitaxel (starting dose: 100 mg/m(2)), gemcitabine (starting dose: 800 mg/m(2)) and oxaliplatin (starting dose: 50 mg/m(2)) on days 1 and 15 in cycles of every 4 weeks. DLTs were evaluated during the first cycle. RESULTS: Twenty-seven patients (median age 65 years) with performance status 0-1 were treated on six dose escalation levels. Eleven patients (40.7%) were chemotherapy naive, six (22.2%) had received 1 prior chemotherapy regimen and ten (37.1%) 2 or more. The DLT level was reached at the doses of paclitaxel 110 mg/m(2), gemcitabine 1,150 mg/m(2) and LOHP 70 mg/m(2). The dose-limiting events were grade 4 neutropenia and grade 3 febrile neutropenia. Neutropenia was the most common adverse event. A median of 3 cycles per patient was administered. One complete and five partial responses were observed in patients with ovarian carcinoma, NSCLC, urothelial cancer, mesothelioma and cancer of unknown primary. No pharmacokinetic drug interactions were detected. CONCLUSIONS: The recommended doses for future phase II studies of this combination are paclitaxel 110 mg/m(2), gemcitabine 1,000 mg/m(2) and oxaliplatin 70 mg/m(2) every 2 weeks. The regimen is generally well tolerated and merits further evaluation.en
heal.journalNameCancer Chemother Pharmacolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Saridaki-2009-A dose escalation an.pdf336.92 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons